Addition of carboplatin (Paraplatin) to trastuzumab (Herceptin) plus paclitaxel (Taxol) can enhance significantly treatment response and time to disease progression with acceptable toxicity for women with advanced breast cancer that is positive for the human epidermal receptor HER-2/neu, according to Phase III results.
Nicholas J. Robert, MD, principal investigator and co-chair of the US Oncology Clinical Research Breast Committee, presented the results here December 11th at the 25th Annual San Antonio Breast Cancer Symposium.
Treatment of patients with HER-2/neu-positive advanced breast cancer using the combination of trastuzumab and paclitaxel has been shown in previous studies to be superior to paclitaxel alone, Dr. Robert said. “Data also show a synergistic relationship between trastuzumab and platinum analogues.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!